Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT01003028
Starting soon Phase 4

Reduction of Remifentanil-related Complications

NCT01003028 · tracked via the Priya Life Science South Korea tracker
Sponsor
Seoul National University Hospital
Phase
Phase 4
Started
2024-11-01
Last updated
2023-12-01

Condition(s) studied

Anesthesia

Investigational drug(s) / intervention(s)

Remifentanil (Limited) - Target Controlled Infusion systemRemifentanil (Control) - Target Controlled Infusion system

Remifentanil (Limited) - Target Controlled Infusion system: Limit max plasma concentration to 9.8 ng/ml

Remifentanil (Control) - Target Controlled Infusion system: Use 20 ng/ml as max plasma concentration

Study summary

This study is intended to evaluate the effect of decreasing the maximum plasma concentration target of remifentanil of the Target Controlled Infusion system on the the incidence of major and minor side-effects.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * 18-70 year old * ASA class 1-3 scheduled for elective surgery Exclusion Criteria: * history of neurologic or mental disorder * uncontrolled pulmonary or cardiovascular disease * history of adverse reactions to opioids * history of drug abuse

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Seoul National University Hospital Seoul South Korea

More Seoul National University Hospital trials in South Korea

Implementation of the ERAS in Colorectal Cancer Patients: a Single Arm Study Enrolling by invitation
Individualized Versus Conventional Perioperative Blood Pressure Management Recruiting
PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate Active, not recruiting
Intrathecal Morphine Injection Versus Continuous Wound Infiltration After Pancreaticoduodenectomy Recruiting
Safety & Efficacy of a Novel Asymmetrical Linear Stapler (NALS) for Securing Distal Resection Margin in Laparoscopic Rectal Cancer Surgery: Pilot Study Starting soon

Other trials for the same condition

Anesthesia and Cancer Study: Colon Cancer Active, not recruiting
Anesthesia and Non-small Cell Lung Cancer Recurrence Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01003028 on ClinicalTrials.gov ↗ ← All trials in South Korea